Cargando…
Discovery of new Schistosoma mansoni aspartyl protease inhibitors by structure-based virtual screening
BACKGROUND: Schistosomiasis is a neglected tropical disease caused by trematodes of the genus Schistosoma, with a limited treatment, mainly based on the use of praziquantel (PZQ). Currently, several aspartic proteases genes have already been identified within the genome of Schistosoma species. At le...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Instituto Oswaldo Cruz, Ministério da Saúde
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481938/ https://www.ncbi.nlm.nih.gov/pubmed/37672425 http://dx.doi.org/10.1590/0074-02760230031 |
_version_ | 1785102084481220608 |
---|---|
author | Gomes, Bárbara Figueira Senger, Mario Roberto Moreira-Filho, José Teófilo de Vasconcellos, Fabio Jorge Dantas, Rafael Ferreira Owens, Raymond Andrade, Carolina Horta Neves, Bruno Junior Silva-Junior, Floriano Paes |
author_facet | Gomes, Bárbara Figueira Senger, Mario Roberto Moreira-Filho, José Teófilo de Vasconcellos, Fabio Jorge Dantas, Rafael Ferreira Owens, Raymond Andrade, Carolina Horta Neves, Bruno Junior Silva-Junior, Floriano Paes |
author_sort | Gomes, Bárbara Figueira |
collection | PubMed |
description | BACKGROUND: Schistosomiasis is a neglected tropical disease caused by trematodes of the genus Schistosoma, with a limited treatment, mainly based on the use of praziquantel (PZQ). Currently, several aspartic proteases genes have already been identified within the genome of Schistosoma species. At least one enzyme encoded from this gene family (SmAP), named SmCD1, has been validated for the development of schistosomicidal drugs, since it has a key role in haemoglobin digestion by worms. OBJECTIVE: In this work, we integrated a structure-based virtual screening campaign, enzymatic assays and adult worms ex vivo experiments aiming to discover the first classes of SmCD1 inhibitors. METHODS: Initially, the 3D-structures of SmCD1, SmCD2 and SmCD3 were generated using homology modelling approach. Using these models, we prioritised 50 compounds from 20,000 compounds from ChemBridge database for further testing in adult worm aqueous extract (AWAE) and recombinant SmCD1 using enzymatic assays. FINDINGS: Seven compounds were confirmed as hits and among them, two compounds representing new chemical scaffolds, named 5 and 19, had IC(50) values against SmCD1 close to 100 μM while presenting binding efficiency indexes comparable to or even higher than pepstatin, a classical tight-binding peptide inhibitor of aspartyl proteases. Upon activity comparison against mammalian enzymes, compound 50 was selective and the most potent against the AWAE aspartic protease activity (IC(50) = 77.7 μM). Combination of computational and experimental results indicate that compound 50 is a selective inhibitor of SmCD2. Compounds 5, 19 and 50 tested at low concentrations (10 uM) were neither cytotoxic against WSS-1 cells (48 h) nor could kill adult worms ex-vivo, although compounds 5 and 50 presented a slight decrease on female worms motility on late incubations times (48 or 72 h). MAIN CONCLUSION: Overall, the inhibitors identified in this work represent promising hits for further hit-to-lead optimisation. |
format | Online Article Text |
id | pubmed-10481938 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Instituto Oswaldo Cruz, Ministério da Saúde |
record_format | MEDLINE/PubMed |
spelling | pubmed-104819382023-09-07 Discovery of new Schistosoma mansoni aspartyl protease inhibitors by structure-based virtual screening Gomes, Bárbara Figueira Senger, Mario Roberto Moreira-Filho, José Teófilo de Vasconcellos, Fabio Jorge Dantas, Rafael Ferreira Owens, Raymond Andrade, Carolina Horta Neves, Bruno Junior Silva-Junior, Floriano Paes Mem Inst Oswaldo Cruz Research Article BACKGROUND: Schistosomiasis is a neglected tropical disease caused by trematodes of the genus Schistosoma, with a limited treatment, mainly based on the use of praziquantel (PZQ). Currently, several aspartic proteases genes have already been identified within the genome of Schistosoma species. At least one enzyme encoded from this gene family (SmAP), named SmCD1, has been validated for the development of schistosomicidal drugs, since it has a key role in haemoglobin digestion by worms. OBJECTIVE: In this work, we integrated a structure-based virtual screening campaign, enzymatic assays and adult worms ex vivo experiments aiming to discover the first classes of SmCD1 inhibitors. METHODS: Initially, the 3D-structures of SmCD1, SmCD2 and SmCD3 were generated using homology modelling approach. Using these models, we prioritised 50 compounds from 20,000 compounds from ChemBridge database for further testing in adult worm aqueous extract (AWAE) and recombinant SmCD1 using enzymatic assays. FINDINGS: Seven compounds were confirmed as hits and among them, two compounds representing new chemical scaffolds, named 5 and 19, had IC(50) values against SmCD1 close to 100 μM while presenting binding efficiency indexes comparable to or even higher than pepstatin, a classical tight-binding peptide inhibitor of aspartyl proteases. Upon activity comparison against mammalian enzymes, compound 50 was selective and the most potent against the AWAE aspartic protease activity (IC(50) = 77.7 μM). Combination of computational and experimental results indicate that compound 50 is a selective inhibitor of SmCD2. Compounds 5, 19 and 50 tested at low concentrations (10 uM) were neither cytotoxic against WSS-1 cells (48 h) nor could kill adult worms ex-vivo, although compounds 5 and 50 presented a slight decrease on female worms motility on late incubations times (48 or 72 h). MAIN CONCLUSION: Overall, the inhibitors identified in this work represent promising hits for further hit-to-lead optimisation. Instituto Oswaldo Cruz, Ministério da Saúde 2023-09-01 /pmc/articles/PMC10481938/ /pubmed/37672425 http://dx.doi.org/10.1590/0074-02760230031 Text en https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License |
spellingShingle | Research Article Gomes, Bárbara Figueira Senger, Mario Roberto Moreira-Filho, José Teófilo de Vasconcellos, Fabio Jorge Dantas, Rafael Ferreira Owens, Raymond Andrade, Carolina Horta Neves, Bruno Junior Silva-Junior, Floriano Paes Discovery of new Schistosoma mansoni aspartyl protease inhibitors by structure-based virtual screening |
title | Discovery of new Schistosoma mansoni aspartyl protease inhibitors by structure-based virtual screening |
title_full | Discovery of new Schistosoma mansoni aspartyl protease inhibitors by structure-based virtual screening |
title_fullStr | Discovery of new Schistosoma mansoni aspartyl protease inhibitors by structure-based virtual screening |
title_full_unstemmed | Discovery of new Schistosoma mansoni aspartyl protease inhibitors by structure-based virtual screening |
title_short | Discovery of new Schistosoma mansoni aspartyl protease inhibitors by structure-based virtual screening |
title_sort | discovery of new schistosoma mansoni aspartyl protease inhibitors by structure-based virtual screening |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481938/ https://www.ncbi.nlm.nih.gov/pubmed/37672425 http://dx.doi.org/10.1590/0074-02760230031 |
work_keys_str_mv | AT gomesbarbarafigueira discoveryofnewschistosomamansoniaspartylproteaseinhibitorsbystructurebasedvirtualscreening AT sengermarioroberto discoveryofnewschistosomamansoniaspartylproteaseinhibitorsbystructurebasedvirtualscreening AT moreirafilhojoseteofilo discoveryofnewschistosomamansoniaspartylproteaseinhibitorsbystructurebasedvirtualscreening AT devasconcellosfabiojorge discoveryofnewschistosomamansoniaspartylproteaseinhibitorsbystructurebasedvirtualscreening AT dantasrafaelferreira discoveryofnewschistosomamansoniaspartylproteaseinhibitorsbystructurebasedvirtualscreening AT owensraymond discoveryofnewschistosomamansoniaspartylproteaseinhibitorsbystructurebasedvirtualscreening AT andradecarolinahorta discoveryofnewschistosomamansoniaspartylproteaseinhibitorsbystructurebasedvirtualscreening AT nevesbrunojunior discoveryofnewschistosomamansoniaspartylproteaseinhibitorsbystructurebasedvirtualscreening AT silvajuniorflorianopaes discoveryofnewschistosomamansoniaspartylproteaseinhibitorsbystructurebasedvirtualscreening |